Researchers in this study are comparing two different treatments for hairy cell leukemia. The people in this study have hairy cell leukemia that has not yet been treated. In addition, their leukemia has a genetic mutation (change) called BRAF V600E.
The standard treatment for hairy cell leukemia is chemotherapy with cladribine plus rituximab. The study treatment is vemurafenib plus obinutuzumab. Vemurafenib and obinutuzumab (non-chemotherapy drugs) have been used to treat hairy cell leukemia. They may cause fewer side effects than the standard chemotherapy drugs, including a lower risk of infections and need for transfusions.
If you join this study, you will be randomly assigned to get one of these treatments:
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
To join this study, there are a few conditions. You must:
Phase 2
Enrollment: 86 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Columbus, OH
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message